Evidence map›Paper›PMID 41706274›Full record

ArticleBulletin of experimental biology and medicine2025

Efficacy of Submicron Vaterite-Based Drug Carriers in Mitigating Doxorubicin-Induced Liver Injury.

A O Kuznetsov, Yu N Vlasicheva, A N Ivanov, E V Lengert, A V Ermakov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A O KuznetsovInstitute of Molecular Theranostics, I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Yu N VlasichevaMendeleev University of Chemical Technology of Russia, Moscow, Russia.
A N IvanovV. I. Razumovsky Saratov State Medical University, Ministry of Health of the Russian Federation, Saratov, Russia.
E V LengertInstitute of Molecular Theranostics, I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
A V ErmakovInstitute of Molecular Theranostics, I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia. a.ermakov@lift.center.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of drug carriers based on submicron vaterite particles in mitigating doxorubicin-induced liver damage was evaluated. The use of alginate-coated vaterite particles significantly reduced hepatic transaminase levels in rats in comparison with the control group, which received doxorubicin encapsulated in PEG-coated carriers. The incorporation of pH-sensitive vaterite carriers enabled stable retention of doxorubicin, thereby minimizing its off-target release and attenuating hepatotoxicity. These findings demonstrate the potential of alginate-coated vaterite particles to reduce the systemic toxicity associated with doxorubicin chemotherapy and highlight their promise as a platform for developing safer, more effective anticancer therapies with improved therapeutic indices.

Indexed as

Antibiotics, AntineoplasticCalcium CarbonateChemical and Drug Induced Liver InjuryDoxorubicinDrug CarriersAlanine TransaminaseAlginatesAnimalsAspartate AminotransferasesGlucuronic AcidHexuronic AcidsLiverMalePolyethylene GlycolsRatsAlanine TransaminaseAlginatesAntibiotics, AntineoplasticAspartate AminotransferasesCalcium CarbonateDoxorubicinDrug CarriersGlucuronic AcidHexuronic AcidsPolyethylene GlycolsALTASTdoxorubicinmesoporous vateritetargeted drug delivery

Identifiers

PMID41706274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.